Assetmark Inc. Has $7.88 Million Position in Sanofi (SNY)
Assetmark Inc. lifted its stake in shares of Sanofi (NYSE:SNY) by 34.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 158,305 shares of the company’s stock after buying an additional 40,484 shares during the period. Assetmark Inc.’s holdings in Sanofi were worth $7,882,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its position in Sanofi by 3.3% in the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock worth $701,156,000 after purchasing an additional 443,799 shares during the last quarter. Founders Financial Securities LLC purchased a new position in Sanofi in the second quarter worth $907,000. Goodwin Daniel L purchased a new position in Sanofi in the second quarter worth $239,000. AMG National Trust Bank boosted its position in Sanofi by 5.3% in the second quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock worth $2,464,000 after purchasing an additional 2,594 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. 9.30% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on the company. Barclays PLC raised Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Argus reissued a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research report on Friday, September 1st. Finally, raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. Sanofi presently has a consensus rating of “Hold” and a consensus target price of $53.50.
In other news, major shareholder Sanofi purchased 105,820 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.00% of the stock is owned by corporate insiders.
Shares of Sanofi (SNY) traded up $0.41 during midday trading on Wednesday, hitting $45.20. The stock had a trading volume of 399,508 shares, compared to its average volume of 1,513,268. Sanofi has a 1 year low of $38.45 and a 1 year high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The stock has a market cap of $111,753.23, a PE ratio of 13.98, a PEG ratio of 2.44 and a beta of 0.88.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.